Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of its...
NEW YORK, Nov. 17 /PRNewswire/ -- Standard & Poor's will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices: -- Wyeth (NYSE:WYE) will replace...
Invitrogen Corporation (NASDAQ:IVGN) today announced progress against its integration plans regarding its pending merger with Applied Biosystems. The company announced that...
DALLAS, Oct. 30 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting:...
Invitrogen Corporation (Nasdaq:IVGN) today announced results for its third quarter ended September 30,?2008. Revenues for the third quarter were $362?million, an increase...
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of a new...
As a part of its continued commitment to environmental sustainability, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research...
Invitrogen Corporation (NASDAQ:IVGN) today announced that the company has completed a significant milestone in the integration planning for the Applied Biosystems combination...
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today congratulates the three winners of the...
Families of Spinal Muscular Atrophy (FSMA, www.curesma.org), Invitrogen Corporation (NASDAQ:IVGN)(www.invitrogen.com), and deCODE chemistry & biostructures...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
